1 / 29

Multi-site Performance Monitoring in Batch Pharmaceutical Production

Multi-site Performance Monitoring in Batch Pharmaceutical Production. Chris Wong Centre for Process Analytics and Control Technology School of Chemical Engineering and Advanced Materials University of Newcastle. Presentation Structure.

nyx
Télécharger la présentation

Multi-site Performance Monitoring in Batch Pharmaceutical Production

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Multi-site Performance Monitoring in Batch Pharmaceutical Production Chris Wong Centre for Process Analytics and Control Technology School of Chemical Engineering and Advanced Materials University of Newcastle

  2. Presentation Structure • Manufacturing challenges facing the chemical and pharmaceutical industries • Process description • Batch performance monitoring overview • Statistical data analysis • Individual Principal Component Analysis (PCA) model • Combined PCA model – Removal of global mean • Combined PCA model – Removal of local mean • Multi-group PCA model • Conclusions and potential industrial impact

  3. Manufacturing Challenges • Reduce time between product development and full-scale production • Achieve right-first-time production • Manufacture consistently high quality product with minimal environmental impact • Transfer product from one vessel to another, i.e. fingerprinting • Transfer process between sites

  4. Information Knowledge Data Universities Industries Government Technology Transfer The Ultimate Goal

  5. Aims • Understand and identify differences in process behaviour where a product is manufactured at two different sites • Remove impact of differences between site operations such as those relative to operational scale • Focus on within process variability One Multi-site Model versus Many Single Site Models

  6. Process From Previous Stage Process To Next Stage Input Material + Reactant Product Process Measurements Product Quality Measurements Process Description • The process is a single stage within a multi-stage synthetic route for the production of an active pharmaceutical ingredient

  7. Process Variables Site A 57 batches 5 process variables • Agitation Rate • Level Site B 152 batches 4 process variables • Vapour Temperature • 3 common process variables • Reactor Temperature • Reactor Pressure • Reactant Addition Rate

  8. Batch Performance Monitoring • Multi-way unfolding (Nomikos and MacGregor, 1994) Time (K) Batches (I) Variables (J) V(1) V(2) V(J) Batches Time

  9. Multi-way PCA Model • Apply PCA to the unfolded equalised batch data • Extract the principal component score vectors • Batch performance can be investigated Score vector ~ examining batch variation V(1) V(2) V(J) Batches Time Loading vector ~ examining process behaviour over time for different variables

  10. Batch Length Equalisation • To apply multi-way PCA, batch lengths are required to be of equal duration • Two methods were implemented: • Multivariate Dynamic Time Warping (DTW) • A method to match features in a data pattern, or profile, to a reference profile • Cutting to minimum length • To include only the important period of operation for analysis

  11. Batch Length Equalisation Initial cleaned data After applying DTW Temperature Pressure

  12. Individual PCA Model – Site A Bivariate scores plot PC1 vs PC2 Bivariate scores plot after removal of batch 15 PC1 vs PC2

  13. Individual PCA Model – Site A Level Univariate loadings plot PC1

  14. Individual PCA Model – Site B Reactant Addition Rate Bivariate scores plot PC1 vs PC2 Contribution plot for batch 127

  15. Site A Site A Site A Standardisation Combining 2 data matrices Site B Site B Site B Mean trajectory removed through entire column Removal of Global Mean

  16. Removal of Global Mean Site A Global Mean Site B

  17. Combined PCA Model – Removal of Global Mean Blue: Site A Black: Site B Bivariate scores plots PC1 vs PC2 PC3 vs PC4

  18. Combined PCA Model – Removal of Global Mean Reactor Temperature Reactor Pressure Reactant Addition Rate Differential contribution plot

  19. Combined PCA Model – Removal of Local Mean Site A Site A Site A Combining 2 data matrices Standardisation Site B Site B Site B Mean trajectory removed from entire column at individual site

  20. Removal of Local Mean Site A Local Mean for Site A Local Mean for Site B Site B

  21. Combined PCA Model – Removal of Local Mean Reactant Addition Rate Bivariate scores plot PC1 vs PC2 Univariate loadings plot PC1

  22. Multi-group PCA Model • An extension to traditional multi-way PCA • Based on the assumption that a common eigenvector subspace exists for the sample variance-covariance matrix of individual sites • Through the pooled sample variance-covariance matrix (S), the principal component loadings are calculated

  23. Multi-group PCA Model Site A Site A Site A s1 S Pool the covariance matrices from the two sites Calculate the covariance matrix Standardisation Site B Site B Site B s2

  24. Multi-group PCA Model Bivariate scores plot, PC1 vs PC2

  25. Multi-group PCA Model Site A Site B Common variables Univariate loadings plot, PC1

  26. Multi-group PCA Model • Developed a single model for monitoring two different sites • Enable an enhanced understanding of the subtle differences between two sites • Minimise loss of information (all variables were retained) • Eliminate problems caused by operational scale • Help facilitate the transfer of a process to a new site

  27. Conclusions • Different approaches to multi-site monitoring have been demonstrated by their application to data from a drug intermediate process • The capabilities of multi-group models were shown to have acceptable detection and diagnostic properties

  28. Potential Industrial Impact • Faster knowledge transfer from R&D, pilot plant to full scale manufacture • Provision of model portability and transferability across different plants • Provision of tighter product specification and minimising quality differences between plants

  29. Acknowledgments • Professor Elaine Martin and Professor Julian Morris • Mr. Richard Escott, GSK • Dr. John O’Shea and Dr. Chris Killen, GSK • Centre for Process Analytics and Control Technology • EPSRC • GlaxoSmithKline • The UK Overseas Research Students (ORS) Scheme

More Related